InMed Pharmaceuticals Reports Full Year Fiscal 2024 Financial Results and Provides Business Update

Rhea-AI Summary

InMed Pharmaceuticals reported financial results for fiscal year 2024 and provided a business update. Key highlights include:

• $4.6M in revenues, an 11% increase over the previous year
• Net loss of $7.7M, compared to $7.9M in the previous year
• Cash position of $6.6M as of June 30, 2024
• Advancement of INM-901 program for Alzheimer's disease
• Development of INM-089 for Age-Related Macular Degeneration (AMD)
• Strengthened patent portfolio with three new U.S. patents

The company made significant progress in its pharmaceutical pipeline, focusing on Alzheimer's disease and dry AMD. INM-901 demonstrated multiple mechanisms of action and potential disease-modifying effects in preclinical studies. INM-089 showed positive pharmacological effects in dry AMD treatment.

Positive

• Revenue increased by 11% to $4.6M in fiscal year 2024
• Net loss decreased from $7.9M to $7.7M year-over-year
• Advanced INM-901 program for Alzheimer's disease with promising preclinical results
• Developed INM-089 for AMD treatment with positive pharmacological effects
• Strengthened patent portfolio with three new U.S. patents

Negative

• Continued net loss of $7.7M for the fiscal year
• Cash position of $6.6M expected to fund operations only until Q4 2024
• Increase in research and development expenses expected in future periods

Insights

Financial Analyst

InMed Pharmaceuticals' fiscal 2024 results show mixed signals. The company reported $4.6 million in revenue, an 11% increase year-over-year, primarily driven by its BayMedica subsidiary. However, the net loss remained relatively stable at $7.7 million, compared to $7.9 million in the previous year.

The company's cash position of $6.6 million as of June 30, 2024, is concerning, as it's only expected to fund operations until Q4 2024. This tight runway may necessitate additional financing in the near future, potentially leading to dilution for existing shareholders.

On the positive side, InMed has made progress in its pharmaceutical pipeline, particularly with INM-901 for Alzheimer's disease and INM-089 for Age-Related Macular Degeneration. These programs, if successful, could significantly boost the company's long-term prospects. However, they are still in preclinical stages, meaning substantial time and capital will be required before potential commercialization.

Investors should closely monitor the company's cash burn rate and any potential capital raises in the coming quarters. The success of BayMedica's commercial operations and advancements in the drug development pipeline will be important for InMed's future performance.

Medical Research Analyst

InMed's progress in its pharmaceutical pipeline is noteworthy, particularly the advancement of INM-901 for Alzheimer's disease. The multi-faceted approach of this drug candidate, targeting both CB1/CB2 receptors and PPARs, aligns with the current industry understanding that complex diseases like Alzheimer's may require combination therapies or multi-target approaches.

The preclinical data for INM-901 is encouraging, showing neuroprotective effects, reduced neuroinflammation and improved cognitive function. The oral administration route could provide a significant advantage over current treatments if efficacy is maintained in human trials.

For INM-089 in dry AMD, the reported neuroprotective effects and potential efficacy in geographic atrophy are promising. However, it's important to note that both programs are still in early stages and success in preclinical studies doesn't guarantee clinical efficacy.

The company's focus on strengthening its patent portfolio is a positive step, potentially adding value to its drug candidates. However, investors should be aware that the path to market for these drugs is long and uncertain, with significant clinical and regulatory hurdles ahead.

• Advances INM-901 program targeting several biological pathways associated with Alzheimer's disease
• Further develops INM-089 demonstrating neuroprotection in the treatment of dry Age-related Macular Degeneration
• $4.6M revenues in fiscal year 2024, representing a 11% increase over the previous fiscal year

Vancouver, British Columbia--(Newsfile Corp. - September 30, 2024) - InMed Pharmaceuticals Inc. (Nasdaq: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announced financial results for the fiscal year ending June 30, 2024 and provided a business update on the pharmaceutical drug development programs as well as the commercial segment for its wholly-owned subsidiary, BayMedica, LLC ("BayMedica").

The Company's full financial statements and related MD&A for the fiscal year ended June 30, 2024, are available at www.inmedpharma.com and at www.sedar.com.

Financial and operating highlights for fiscal 2024:

• As of June 30, 2024, the Company's cash, cash equivalents and short-term investments were $6.6M
• For the year ended June 30, 2024, the Company recorded a net loss of $7.7M, compared with a net loss of $7.9M for the previous year
• Advanced INM-901 program with long-term preclinical studies, targeting multiple mechanisms of action in the treatment of Alzheimer's disease
• Launched INM-089 preclinical program in the treatment of Age-Related Macular Degeneration ("AMD") and reported preclinical data demonstrating positive pharmacological effects
• Strengthened patent portfolio with the issuance of three new U.S. patents across formulation and method of use, manufacturing and drug delivery formulation
• Total sales for BayMedica were $4.6M in fiscal year 2024, representing an 11% increase over the previous fiscal year

Eric A. Adams, InMed Chief Executive Officer commented, "In fiscal year 2024, we made significant progress in our pharmaceutical pipeline, advancing two preclinical programs targeting Alzheimer's disease and dry AMD. Both these programs utilize proprietary small molecule drug candidates that activate both the CB1 and CB2 receptors, as well as other disease-relevant receptors. We are especially encouraged by the rapid advancement of the INM-901 program, which has been in development for less than a year since the drug candidate was selected last October."

The Alzheimer's treatment landscape has shifted significantly in recent years, underscoring the need for innovative, disease-modifying therapies and more convenient treatment options. Industry leaders now recognize that treating a complex disease like Alzheimer's will likely require a combination of therapies or a multi-faceted approach. With INM-901, InMed has developed an orally available small molecule that has demonstrated disease-modifying effects in preclinical studies by targeting multiple biological pathways, positioning us at the forefront of innovative Alzheimer's research."

Business Update

Pharmaceutical Development Programs

INM-901: Targeting several biological pathways associated with Alzheimer's disease

INM-901 is a proprietary small molecule drug candidate with multiple mechanisms of action in development as a potential treatment for Alzheimer's disease. Throughout fiscal 2024, the Company announced several key findings for INM-901:

• A preferential signaling agonist of the CB1/CB2 receptors and has been shown to have neuroprotective effects, helping protect the neurons in the brain from damage and cell death
• Impacts the peroxisome proliferator-activated receptors ("PPARs"), which have been shown to play an important role in diabetes and are also considered as one of the potential therapeutic targets for neurodegenerative disorders such as Alzheimer's disease.
• Demonstrates reduced neuroinflammation and improved neurite growth and neuronal function, indicating the potential to restore damage caused by Alzheimer's disease.
• Can be administered orally and achieve therapeutic levels in the brain comparable to those obtained through intraperitoneal ("IP") injection, offering many potential advantages over routes of administration of the currently approved products; and
• Demonstrates significant improvement in cognitive function, memory, locomotor activity, anxiety-based behavior and sound awareness in long term preclinical behavioural studies

InMed continues to accelerate the development of its Alzheimer's program, with additional molecular analysis of a preclinical long-term dosing study currently underway to better define the mechanisms of action. Data read-out is expected in the coming months. Additionally, the development of the chemistry, manufacturing, and controls ("CMC") for both the drug substance and the drug product formulation is ongoing, with GLP studies in the planning stages to support an IND submission.

INM-089: Neuroprotection in the treatment of dry AMD

INM-089 is a proprietary small molecule drug candidate being studied in the treatment of dry AMD. Throughout fiscal 2024, the Company reported preclinical data for INM-089 demonstrating positive pharmacological effects including.

• Data indicates that INM-089 may be more effective as a therapeutic treatment for dry AMD compared to neovascular, or wet, AMD
• More specifically, data suggests INM-089 may be an important candidate for geographic atrophy ("GA") which is a more advanced stage of dry AMD
• Enhanced neuroprotection of photoreceptors as well as improved photoreceptor function
• Improved integrity of retinal pigment epithelium
• Reduction in extracellular autofluorescent deposits, a hallmark of dry AMD.

INM-755: Dermatology Program - Continuing to seek strategic partnerships

Further development of the INM-755 CBN cream is expected to extend beyond its application in Epidermolysis bullosa ("EB"), potentially encompassing broader indications related to chronic, severe itch with larger target populations and potential commercial opportunities. InMed continues to assess potential partnership opportunities for the advancement of INM-755.

Continues to strengthen intellectual property portfolio

InMed continues to develop its patent portfolio and increase the commercial value of its programs to ensure the long-term protection of our drug research and development efforts. In recent months, InMed has been issued three U.S. patents: one for its formulation and method of use in the treatment of EB and related connective tissue disorders, one for a biosynthesis manufacturing processes and one for an ocular drug delivery formulation.

BayMedica commercial subsidiary

BayMedica, a leading supplier of non-intoxicating rare cannabinoids to the health and wellness sector, has experienced sustained revenue growth during the fiscal year 2024, reaching $4.6M, representing an 11% increase over the previous year. Sales and marketing efforts will remain focused on products that contribute highest margins, where BayMedica continues to hold a strong competitive position.

Financial commentary:

For the year ended June 30, 2024, the Company recorded a net loss of $7.7M, compared with a net loss of $7.9M for the previous year.

Research and development and patents expenses were $3.8M for year ended June 30, 2024, compared with $3.7M for the year ended June 30, 2023. However, we expect our research and development expenses to increase significantly in future periods as we continue to implement our business strategy.

The Company incurred general and administrative expenses of $5.3M for the year ended June 30, 2024, compared to $5.8M in the previous year. The decrease was primarily from a combination of changes in the InMed segment, including lower office and admin fees and investor relations expenses. This was offset by a slight increase in sales and marketing expenses within the BayMedica segment.

The Company realized sales of $4.6M in our BayMedica segment for the year ended June 30, 2024, representing an increase of $0.5M, or 11%, for the year ended June 30, 2024, as compared to the year ended June 30, 2023.

As of June 30, 2024, we had cash, cash equivalents and short-term investments of $6.6 million The Company expects its cash will be sufficient to fund its planned operating expenses and capital expend to the end of the fourth quarter of calendar year 2024, depending on the level and timing of realizing BayMedica revenues as well as the level and timing of the Company's operating expenses.

Table 1. Consolidated Balance Sheet

InMed Pharmaceuticals Inc. 
CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited)
Expressed in U.S. Dollars

		June 30,			June 30,
		2024			2023
		(unaudited)
ASSETS		$			$
Current
Cash and cash equivalents		6,571,610			8,912,517
Short-term investments		43,064			44,422
Accounts receivable (less provision for credit losses of $nil and $66,775 in June 30, 2024 and 2023, respectively)		352,838			260,399
Inventories, net		1,244,324			1,616,356
Prepaids and other current assets		477,749			498,033
Total current assets		8,689,585			11,331,727
Non-Current
Property, equipment and ROU assets, net		1,249,999			723,426
Intangible assets, net		1,783,198			1,946,279
Other assets		100,000			104,908
Total Assets		11,822,782			14,106,340
LIABILITIES AND SHAREHOLDERS' EQUITY
Current
Accounts payable and accrued liabilities		1,654,011			1,608,735
Current portion of lease obligations		317,797			375,713
Deferred rent		-			16,171
Total current liabilities		1,971,808			2,000,619
Non-current
Lease obligations, net of current portion		644,865			15,994
Total Liabilities		2,616,673			2,016,613
Commitments and Contingencies (Note 13)
Shareholders' Equity
Common shares, no par value, unlimited authorized shares: 8,918,956 and
3,328,191 as of June 30, 2024 and 2023, respectively, issued and outstanding		82,784,400			77,620,252
Additional paid-in capital		35,368,899			35,741,115
Accumulated deficit		(109,075,759	)		(101,400,209	)
Accumulated other comprehensive income		128,569			128,569
Total Shareholders' Equity		9,206,109			12,089,727
Total Liabilities and Shareholders' Equity		11,822,782			14,106,340
Related Party Transactions (Note 14)

 

Table 2. Consolidated Statements of Operations

InMed Pharmaceuticals Inc.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited)
Expressed in U.S. Dollars

		Year Ended
		June 30
		2024			2023
		$			$
Sales		4,597,730			4,135,561
Cost of sales		3,496,817			2,732,525
Gross profit		1,100,913			1,403,036
Operating Expenses
Research and development and patents		3,765,028			3,732,056
General and administrative		5,250,715			5,847,518
Amortization and depreciation		219,600			202,249
Foreign exchange loss		61,921			48,175
Total operating expenses		9,297,264			9,829,998
Other Income (Expense)
Interest and other income		527,901			492,440
Loss before income taxes		(7,668,450	)		(7,934,522	)
Tax expense		(7,100	)		(13,100	)
Net loss for the period		(7,675,550	)		(7,947,622	)
Net loss per share for the period
Basic and diluted		(1.01	)		(3.25	)
Weighted average outstanding common shares
Basic and diluted		7,621,075			2,448,458

 

Table 3. Consolidated Statements of Cash Flows

InMed Pharmaceuticals Inc.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited)
For the year ended June 30, 2024 and 2023
Expressed in U.S. Dollars

		June 30, 2024			June 30, 2023
Cash provided by (used in):		$			$
Operating Activities
Net loss		(7,675,550)			(7,947,622)
Items not requiring cash:
Amortization and depreciation		219,600			202,249
Share-based compensation		137,714			278,155
Amortization of right-of-use assets		384,918			393,748
Interest income received on short-term investments		(1,250	)		(803	)
Unrealized foreign exchange loss		12,262			1,183
Inventory write-down		305,812			308,937
Credit losses		-			46,775
Changes in operating assets and liabilities:
Inventories		66,220			565,561
Prepaids and other currents assets		20,284			299,192
Other non-current assets		4,908			5,507
Accounts receivable		(92,439	)		(219,147	)
Accounts payable and accrued liabilities		45,282			(806,530	)
Deferred rent		(16,171	)		16,171
Lease obligations		(397,422	)		(426,575	)
Total cash used in operating activities		(6,985,832	)		(7,283,199	)
Investing Activities
Payment of acquisition consideration		-			(500,000	)
Payment of deposit on equipment		-			(1,790	)
Sale of short-term investments		42,082			42,268
Purchase of short-term investments		(42,082	)		(42,268	)
Purchase of property and equipment		(9,293	)		(160,014	)
Total cash (used in) provided by investing activities		(9,293	)		(661,804	)
Financing Activities
Shares issued for cash
share issuance costs
Proceeds from the exercise of pre-funded warrants		175			646
Proceeds from private placement net of issuance costs		4,654,043			10,680,008
Total cash provided by financing activities		4,654,218			10,680,654
Increase in cash during the period		(2,340,907	)		2,735,649
Cash and cash equivalents beginning of the period		8,912,517			6,176,866
Cash and cash equivalents end of the period		6,571,610			8,912,515
SUPPLEMENTARY CASH FLOW INFORMATION:
Cash Paid During the Year for:
Income taxes	$	-		$	-
Interest	$	-		$	-
SUPPLEMENTARY DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:
Fair value of warrant modification recorded as equity issuance costs	$	3,508,749		$	-
Preferred investment options to its placement agent	$	325,699		$	691,483
Recognition of Right-of-use asset and corresponding operating lease liability	$	968,376		$	-

 

About InMed

InMed Pharmaceuticals is a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates targeting the CB1/CB2 receptors. InMed's pipeline consists of three drug development programs in the treatment of Alzheimer's, ocular and dermatological indications. Together with our subsidiary BayMedica, we are a global leader in the manufacturing, development and commercialization of products based on rare cannabinoids and their proprietary, small molecule drug analogs. For more information, visit www.inmedpharma.com.

Investor Contact:

Colin Clancy
Vice President, Investor Relations
and Corporate Communications
T: +1.604.416.0999
E: cclancy@inmedpharma.com

Cautionary Note Regarding Forward-Looking Information:

This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking information") within the meaning of applicable securities laws. Forward-looking information is based on management's current expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Forward-looking information in this news release includes statements about: expecting revenue fluctuations based on distributor order patterns; remaining optimistic about the long-term growth potential in the rare cannabinoids sector as the business dynamics and commercial opportunities continue to mature; advancing our pharmaceutical pipeline using rare cannabinoids for potential therapeutic applications in dermatology, ocular and neurodegenerative disease; the efficacy of INM-901, INM-901's ability to treat Alzheimer's, marketability and uses for INM-901, the results of further studies into INM-901 and acceleration of the development of InMed's Alzheimer's program; the efficacy of INM-089, INM-089's ability to treat AMD, marketability and uses for INM-089, the results of further studies into INM-089 and the further development of InMed's AMD program; further development and commercial uses of the INM-755; expectations that the Company's cash will be sufficient to fund its planned operating expenses and capital expenditure requirements to the end of the fourth quarter of calendar year 2024.

Additionally, there are known and unknown risk factors which could cause InMed's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein. A complete discussion of the risks and uncertainties facing InMed's stand-alone business is disclosed in InMed's Annual Report on Form 10-K and other filings with the Securities and Exchange Commission on www.sec.gov.

All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/224716

FAQ

What were InMed Pharmaceuticals' (INM) revenue and net loss for fiscal year 2024?

InMed Pharmaceuticals (INM) reported revenues of $4.6M for fiscal year 2024, an 11% increase over the previous year. The company's net loss was $7.7M, compared to $7.9M in the previous fiscal year.

What progress has InMed Pharmaceuticals (INM) made with its INM-901 program for Alzheimer's disease?

InMed Pharmaceuticals (INM) has advanced its INM-901 program for Alzheimer's disease, demonstrating multiple mechanisms of action and potential disease-modifying effects in preclinical studies. The drug candidate has shown neuroprotective effects, reduced neuroinflammation, and improved cognitive function in long-term preclinical behavioral studies.

What is InMed Pharmaceuticals' (INM) cash position as of June 30, 2024?

InMed Pharmaceuticals (INM) reported a cash position of $6.6M as of June 30, 2024. The company expects this cash to be sufficient to fund planned operating expenses and capital expenditures until the end of the fourth quarter of calendar year 2024.

How has InMed Pharmaceuticals (INM) strengthened its patent portfolio in fiscal year 2024?

InMed Pharmaceuticals (INM) strengthened its patent portfolio in fiscal year 2024 by obtaining three new U.S. patents. These patents cover formulation and method of use in treating Epidermolysis bullosa and related connective tissue disorders, biosynthesis manufacturing processes, and an ocular drug delivery formulation.